AKT1 and esophageal squamous cell carcinoma: Treatment with the PI3K inhibitor LY294002 markedly reduced the oncogenic effects of ZNF468 overexpression, indicating that the ZNF468‐AURKA axis promotes tumorigenesis and EMT in ESCC via PI3K/AKT pathway activation.